Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia

British Journal of Haematology

Volumn 157, Issue 2, 2012, Pages 240-248

  Flanagan, Jonathan M ^a   Steward, Shirley ^b   Howard, Thad A ^a   Mortier, Nicole A ^a   Kimble, Amy C ^b   Aygun, Banu ^b   Hankins, Jane S ^b   Neale, Geoffrey A ^b   Ware, Russell E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Gene expression; Hydroxycarbamide; Microarray; Sickle cell anaemia

Indexed keywords

ALPHA GLOBIN; BETA GLOBIN; EPSILON GLOBIN; GAMMA GLOBIN; HEMOGLOBIN F; HYDROXYUREA; RNA;

ADOLESCENT; ADULT; ARTICLE; BCL11A GENE; CHILD; CHROMOSOME STRUCTURE; EIF1 GENE; ELOVL6 GENE; ERYTHROID GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; H3F3A GENE; HBBP1 GENE; HSP90AA1 GENE; HUMAN; HUMAN CELL; IN VIVO STUDY; MAJOR CLINICAL STUDY; OSBPL6 GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN INDUCTION; RAC2 GENE; RETICULOCYTE; RIBOSOME; RNA ISOLATION; RNA TRANSLATION; RPL3 GENE; SCHOOL CHILD; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; SNRPN GENE; TREATMENT OUTCOME;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; FEMALE; FETAL HEMOGLOBIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; HYDROXYUREA; INFANT; MALE; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 84859209995     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09061.x     Document Type: Article

References (29)

1. Benjamini, Y. & Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society B, 57, 289-300.
2. Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., McMahon, R.P. & Bonds, D.R. (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. New England Journal of Medicine, 332, 1317-1322.
3. Cokic, V.P., Smith, R.D., Beleslin-Cokic, B.B., Njoroge, J.M., Miller, J.L., Gladwin, M.T. & Schechter, A.N. (2003) Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. Journal of Clinical Investigation, 111, 231-239.
4. Cokic, V.P., Beleslin-Cokic, B.B., Tomic, M., Stojilkovic, S.S., Noguchi, C.T. & Schechter, A.N. (2006) Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood, 108, 184-191.
5. Dennis, G., Sherman, B.T., Hosack, D.A., Yang, J., Gao, W., Lane, H.C. & Lempicki, R.A. (2003) DAVID: database for annotation, visualization, and integrated discovery. Genome Biology, 4, 3.
6. Dover, G.J. & Boyer, S.H. (1980) Quantitation of hemoglobins within individual red cells: asynchronous biosynthesis of fetal and adult hemoglobin during erythroid maturation in normal subjects. Blood, 56, 1082-1091.
7. Farquhar, M.N., Turner, P.A., Papayannopoulou, T., Brice, M., Nienhuis, A.W. & Stamatoyannopoulos, G. (1981) The asynchrony of [gamma]- and [beta]-chain synthesis during human erythroid cell maturation, III. [gamma]- and [beta]-mRNA in immature and mature erythroid clones. Developmental Biology, 85, 403-408.
8. Ferster, A., Vermylen, C., Cornu, G., Buyse, M., Corazza, F., Devalck, C., Fondu, P., Toppet, M. & Sariban, E. (1996) Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood, 88, 1960-1964.
9. Galarneau, G., Palmer, C.D., Sankaran, V.G., Orkin, S.H., Hirschhorn, J.N. & Lettre, G. (2010) Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nature Genetics, 42, 1049-1051.
10. Garner, C., Tatu, T., Reittie, J.E., Littlewood, T., Darley, J., Cervino, S., Farrall, M., Kelly, P., Spector, T.D. & Thein, S.L. (2000) Genetic influences on F cells and other hematologic variables: a twin heritability study. Blood, 95, 342-346.
11. Gladwin, M.T., Shelhamer, J.H., Ognibene, F.P., Pease-Fye, M.E., Nichols, J.S., Link, B., Patel, D.B., Jankowski, M.A., Pannell, L.K., Schechter, A.N. & Rodgers, G.P. (2002) Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. British Journal of Haematology, 116, 436-444.
12. Heeney, M.M. & Ware, R.E. (2008) Hydroxyurea for children with sickle cell disease. Pediatric Clinics of North America, 55, 483-501.
13. Ikuta, T., Ausenda, S. & Cappellini, M.D. (2001) Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proceedings of the National Academy of Sciences, 98, 1847-1852.
14. Keefer, J.R., Schneidereith, T.A., Mays, A., Purvis, S.H., Dover, G.J. & Smith, K.D. (2006) Role of cyclic nucleotides in fetal hemoglobin induction in cultured CD34 + cells. Experimental Hematology, 34, 1151-1161.
15. Kinney, T.R., Helms, R.W., O'branski, E.E., Ohene-Frempong, K., Wang, W., Daeschner, C., Vichinsky, E., Redding-Lallinger, R., Gee, B., Platt, O.S. & Ware, R.E. (1999) Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood, 94, 1550-1554.
16. Krendel, M., Zenke, F.T. & Bokoch, G.M. (2002) Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton. Nature Cell Biology, 4, 294-301.
17. Lebensburger, J.D., Pestina, T.I., Ware, R.E., Boyd, K.L. & Persons, D.A. (2010) Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica, 95, 1599-1603.
18. Lettre, G., Sankaran, V.G., Bezerra, M.A., Araujo, A.S., Uda, M., Sanna, S., Cao, A., Schlessinger, D., Costa, F.F., Hirschhorn, J.N. & Orkin, S.H. (2008) DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proceedings of the National Academy of Sciences, 105, 11869-11874.
19. Li, S., Klein, E.S., Russo, A.F., Simmons, D.M. & Rosenfeld, M.G. (1989) Isolation of cDNA clones encoding small nuclear ribonucleoparticle-associated proteins with different tissue specificities. Proceedings of the National Academy of Sciences, 86, 9778-9782.
20. Mabuchi, M., Kataoka, H., Miura, Y., Kim, T.S., Kawaguchi, M., Ebi, M., Tanaka, M., Mori, Y., Kubota, E., Mizushima, T., Shimura, T., Mizoshita, T., Tanida, S., Kamiya, T., Asai, K. & Joh, T. (2010) Tumor suppressor, AT motif binding factor 1 (ATBF1), translocates to the nucleus with runt domain transcription factor 3 (RUNX3) in response to TGF-[beta] signal transduction. Biochemical and Biophysical Research Communications, 398, 321-325.
21. Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, M.H. & Klug, P.P. (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England Journal of Medicine, 330, 1639-1644.
22. Steinberg, M.H., McCarthy, W.F., Castro, O., Ballas, S.K., Armstrong, F.D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L. & Waclawiw, M.A. (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematology, 85, 403-408.
23. Tagami, H., Ray-Gallet, D., Almouzni, G. & Nakatani, Y. (2004) Histone H3.1 and H3.3 complexes mediate nucleosome assembly pathways dependent or independent of DNA synthesis. Cell, 116, 51-61.
24. Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D. & Terpos, E. (2010) The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood, 115, 2354-2363.
25. Ware, R.E. & Aygun, B. (2009) Advances in the use of hydroxyurea. American Society of Hematology Education Program, 6, 2-69.
26. Ware, R.E., Eggleston, B., Redding-Lallinger, R., Wang, W.C., Smith-Whitley, K., Daeschner, C., Gee, B., Styles, L.A., Helms, R.W., Kinney, T.R. & Ohene-Frempong, K. (2002) Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood, 99, 10-14.
27. Xu, J., Sankaran, V.G., Ni, M., Menne, T.F., Puram, R.V., Kim, W. & Orkin, S.H. (2010) Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes and Development, 24, 783-798.
28. Zhou, D., Liu, K., Sun, C.W., Pawlik, K.M. & Townes, T.M. (2010) KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. Nature Genetics, 42, 742-744.
29. Zimmerman, S.A., Schultz, W.H., Davis, J.S., Pickens, C.V., Mortier, N.A., Howard, T.A. & Ware, R.E. (2004) Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood, 103, 2039-2045.